Pharvaris to Present Eight Deucrictibant Conference Abstracts Including Phase 3 and CHAPTER-1 Data
PHVS•Pharvaris will present eight abstracts at June 12–15 EAACI Congress, including an oral Phase 3 RAPIDe-3 end-of-progression analysis of deucrictibant immediate-release capsules and Phase 2 CHAPTER-1 open-label extension long-term safety and efficacy findings. The company expects CHAPTER-3 pivotal data in Q3 2026 ahead of marketing-authorization applications.
1. Abstract Acceptance at EAACI Congress
Pharvaris announced the acceptance of one oral presentation and seven flash talk/poster abstracts at the European Academy of Allergy and Clinical Immunology Annual Congress 2026 in Istanbul, scheduled for June 12–15.
2. Focused Clinical Data Presentations
The company will showcase an end-of-progression analysis from the Phase 3 RAPIDe-3 trial of deucrictibant immediate-release capsules, a cardiovascular safety assessment, a kinin biomarker differentiation assay, safety margins for the XR plus IR regimen, qualitative patient-voice insights, and long-term safety and efficacy from the Phase 2 CHAPTER-1 open-label extension prophylaxis study.
3. Upcoming Regulatory and Pipeline Milestones
Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsules as on-demand treatment and is conducting the global Phase 3 CHAPTER-3 study of the extended-release tablet for prophylaxis, with topline data expected in Q3 2026.
